AI is no longer a funding category — it is the baseline. H1 2026 deal flow, the mega-deal surge, a collapsed $32B roll-up, and what record capital concentration means for everyone outside the top twelve.
Six months into 2026, the market our first issue described — capital concentrating, fundamentals rewarded, speculation punished — has intensified rather than normalized. The strongest first quarter since the pandemic peak arrived alongside one of the highest capital concentrations ever recorded, and the industry's leading data house stopped counting "AI deals" altogether.
U.S. digital health startups raised $4.0 billion across 110 deals in Q1 2026 — a full billion more than the $3.0 billion raised across 122 deals in Q1 2025. Deal count fell while dollars rose: average deal size climbed to $36.7 million, the highest quarterly average since Q4 2021, continuing a steady climb that began in late 2024.
Behind the headline is extreme concentration. Twelve mega deals ($100M+ rounds) absorbed 59% of all capital deployed — within a few points of the all-time concentration records set in 2021 (62% in Q1, 61% in Q4). At Q1's pace, 2026 would close with roughly 50 mega deals, nearly double last year's count. Deal flow tracked through June suggests the pace held into Q2.
Our first issue put AI's share of funding — 54% in 2025, up from 37% — on the cover. That metric no longer exists. Rock Health retired its AI-deal tracking analysis this quarter, concluding that the distinction between AI and non-AI digital health companies has blurred beyond usefulness. The companies raising successfully are those moving earliest into complex, workflow-embedded use cases, not those with the loudest AI story.
The consequence is a starker haves-and-have-nots dynamic than at any point in the cycle. The top tier commands nine-figure checks at record speed; the remaining ~100 companies per quarter compete for roughly 40% of deployed capital. For founders outside the winner class, the bar is now contracted revenue, clinical evidence, and workflow integration — not a model demo.
Source: Rock Health quarterly funding reports. 2026 bar reflects Q1 only; at Q1 pace, 2026 would exceed 2025's total. Q1 2026 was the strongest first quarter since Q1 2022.
The largest and most strategically significant rounds closed by AI healthcare companies in the first half of 2026, sourced from Rock Health, CB Insights, Fierce Healthcare's fundraising tracker, and company announcements. Register criteria are unchanged from Issue No. 1 — see Methodology below.
| Company | Amount | Lead Investor(s) | Sector | Model |
|---|---|---|---|---|
|
Whoop
AI-powered wearable health & performance monitoring
Series G — Q1 2026
|
$575M | $10.1B valuation — nearly 3× its last — on $1.1B ARR; reportedly eyeing an IPO | Clinical | B2CDirect-to-consumer wearable subscription |
|
Verily
Alphabet's precision health & data platform
Growth Round — Q1 2026
|
$300M | Undisclosed | Data | B2BSells to pharma, payers & research partners |
|
OpenEvidence
AI medical search & clinical decision support
Series D — Q1 2026 · third round in under a year
|
$250M | Post-$100M revenue; reported daily use by 40%+ of U.S. physicians | Clinical | B2B2CFree to physicians; monetizes via pharma & institutions |
|
Talkiatry
In-network virtual psychiatry at scale
Series D — Q1 2026
|
$212M | Undisclosed | Clinical | B2B2CPatient-facing care; monetizes via payer contracts |
|
Nitra
AI-native operating system for healthcare practices
Series A + B — March 2026
|
$187M | NEA, Pantera Capital, AppWorks & others; 700+ clinics live | Admin | B2BSells to physician practices |
|
Qualified Health
AI adoption & governance platform for health systems
Growth Round — Q1 2026
|
$125M | Undisclosed; reports 400,000 users supported | Admin | B2BSells to health systems |
|
Garner Health
Doctor-quality analytics for employer health plans
Series D — Q1 2026
|
$118M | $1.35B valuation; revenue up 130% year over year | Data | B2BSells to employers & plan sponsors |
|
Trase
Controlled AI agent operating system for regulated industries
Seed — June 2026
|
$107M | ARCH Venture Partners (lead), Red Cell Partners; deployed at Duke Health cardiology | Admin | B2BSells to health systems & regulated enterprises |
|
Midi Health
Insurance-covered virtual care for women in midlife
Series D — Q1 2026 · new unicorn
|
$100M | Undisclosed; 230,000+ patients served | Clinical | B2B2CPatient-facing care; monetizes via insurance coverage |
|
Cadence
AI-powered remote care platform for health systems
Growth Round — June 2026
|
$100M | Spark Capital (lead); Thrive, General Catalyst, Coatue, Duke Health, Memorial Hermann | Clinical | B2BSells to health systems; 100K patients, 20 systems live |
|
Latent
AI prior authorization automation — pure play
Series A — Q1 2026
|
$80M | Undisclosed; riding the CMS-0057-F electronic prior auth deadline | Admin | B2BSells to providers & payers |
|
xCures
Clinical clarity engine — AI structuring of patient records
Series B — June 2026
|
$46M | Innovius Capital (lead) | Data | B2BSells to providers, pharma & life sciences |
|
Adonis
AI revenue cycle platform with prior auth exposure
Series C — Q1 2026
|
$40M | Undisclosed | Admin | B2BSells to provider organizations |
|
Lassie
AI agents to run physician office operations
Series A — June 2026
|
$35M | Andreessen Horowitz (lead) | Admin | B2BSells to physician practices |
Noted outside register scope (non-U.S., per methodology): Alan, the French health insurtech platform, raised ~$555M led by Prosus at a ~$6.3B valuation in June — one of the largest European digital health rounds on record, on reported revenue of ~$925M growing 53%+ annually. Borderline exclusions: Cognito Therapeutics' $105M round (neurostimulation device for Alzheimer's) falls under our device exclusion.
Share of quarterly/annual VC dollars captured by $100M+ rounds. Q1 2026's 59% is one of the highest concentrations Rock Health has ever recorded — a level last seen at the height of the pandemic-era boom, but this time on half the total capital and a fraction of the deal count.
Sources: Rock Health Q1 2026 Funding Overview; Rock Health 2025 Annual Report.
Two changes affect how this register compares to Issue No. 1. First, Rock Health has stopped tracking AI-enabled startups as a distinct funding category — the "54% AI share" statistic from our first cover has no 2026 successor, because AI is now assumed in essentially every fundable digital health company.
Second, definitional spread between data houses is widening. Rock Health counted $4.0B across 110 U.S. digital health deals in Q1; CB Insights, using a broader digital health definition, recorded $7.4B — up from $5.9B in Q4 2025 and its highest reading since Q2 2022 — with 19 mega-rounds capturing 60% of capital and late-stage median deal size more than doubling quarter-over-quarter, from $48M to $108M.
Directionally, the sources agree completely: fewer, larger checks; a shrinking pool of proven winners; eight new unicorns in a single quarter (the most in nearly four years); and a bottom tier competing for what remains. We report Rock Health figures as our headline series for continuity with Issue No. 1, and cite CB Insights where its coverage adds signal.
M&A rebounded sharply in H1 2026 — but the quarter's defining PE story was a deal that didn't happen. The roll-up thesis we spotlighted in Issue No. 1 met its first major stress test, and the market drew a hard new line between regulatory clearance and commercial adoption.
Issue No. 1 profiled New Mountain Capital's Smarter Technologies roll-up as the exemplar of the "AI-native + legacy infrastructure" thesis. In Q1, the firm's far larger sequel — a plan to combine five portfolio companies into a $32 billion AI-focused health tech platform, dubbed Thoreau — fell apart in March over unresolved concerns about debt structure and governance. The lesson is not that the roll-up thesis is dead; it is that the thesis has an execution ceiling. Combining AI capabilities across portfolio companies compounds integration risk, and at $32B scale, capital structure becomes the binding constraint before synergies ever get tested.
The quarter's clearest valuation signal came from radiology AI. DeepHealth paid $269M for Gleamer — a company with 700+ hospital contracts across 44 countries and roughly $30M in projected 2026 revenue. The contrast case is Oxipit, which achieved the world's first CE Class IIb certification for fully autonomous chest X-ray interpretation yet generated under $30K of revenue in 2024. The market's message: regulatory clearance is the entry ticket; commercial adoption is what commands a premium.
OpenAI acquired Torch and Headway picked up the Tezi team — both acqui-hires bringing new talent into digital health products, and both signals that frontier AI labs and scaled digital health platforms are now competing for the same builders. In June, Cityblock acquired Homeward, consolidating value-based care delivery capabilities. Meanwhile, competing agentic voice AI platforms Prosper and Assort raised large rounds within days of each other — a category where consolidation, not coexistence, is the likely endgame.
Digital health M&A deals in Q1 2026 per CB Insights — up 47% from 38 in Q4 2025. Rock Health's narrower count showed 43, itself an uptick from 30.
Q1 2026 health services deal value per PwC — matching one of the sector's strongest recent quarters, with PE driving platform and add-on activity despite policy uncertainty.
PwC's mid-year outlook confirms sponsors continuing to rotate away from reimbursement-exposed assets toward software and services platforms that support care delivery — AI-enabled RCM, utilization management, and workforce tools.
Zero digital health IPOs in H1 2026. After 2025's five-listing reopening, the window narrowed again — not for lack of candidates, but for lack of predictable conditions. Market volatility tied to inflation and oil-price concerns following the war in Iran has made exit timing unusually hard to call, and the year-end watch list is still waiting.
Issue No. 1 flagged agentic AI as the emerging frontier. In H1 it became the category's hottest checkbook: Trase raised a $107M seed — seed — from ARCH after automating 5,000+ monthly faxes at Duke's cardiology division; Lassie landed a16z's lead for AI agents that run physician offices; and rival patient-facing voice AI platforms Prosper and Assort raised within days of each other. The pattern: agents deployed against specific, measurable workflow bottlenecks, sold with capacity-unlocked math rather than headcount-reduction promises.
CMS-0057-F requires payers to make prior authorization fully electronic by January 2027 — now under nine months away — and Q1 deal data shows the market treating the deadline as a forcing function. Latent's $80M Series A is a prior-auth pure play; Adonis' Series C carries heavy prior-auth exposure; and deal activity spans the full stack from seed to exit. Few themes offer a dated, federally mandated adoption catalyst. This one does.
OpenAI, Anthropic, and Perplexity all launched healthcare-specific consumer experiences in H1 — orchestrating health records via partners like b.well and HealthEx and biometric data via wearable and lab partnerships. For digital health companies, the platforms offer reach and a new consumer interface; for investors, the operative analogy is mobile operating systems — entry points may narrow into a duopoly-like structure that everyone else builds on top of, and pays into. Positioning ahead of that consolidation is the trade.
When 12 companies absorb 59% of quarterly capital, the remaining ~100 funded companies split the residue — and the unfunded majority gets nothing. For LPs, winner-class exposure is increasingly expensive; for everyone else, bridge dependency and down-round risk persist from the 2025 pattern (35% of deals flat or down). The bar for institutional capital — contracted revenue, clinical evidence, workflow integration — is now explicit, and companies below it face a structurally worse market than the headline numbers suggest.
Capital markets volatility — inflation and oil-price concerns following the war in Iran chief among the drivers — has made IPO timing unusually unpredictable. Late-stage investors underwriting 2026–2027 exits are carrying duration risk that the Whoop-style private mega-round only partially offsets. A watch list is not a pipeline.
Thoreau's collapse is the cycle's first large-scale proof that the AI roll-up thesis has a failure mode: debt structure and governance complexity scale faster than synergies. Sponsors pursuing multi-asset AI consolidations should expect lenders and co-investors to underwrite integration risk far more skeptically in H2 — and portfolio companies counting on a combination for their exit should have a plan B.
The CMMI ACCESS Model's inaugural cohort announcement is expected in H2 — the single most consequential event on the calendar for outcome-based digital health. Payment rates went live in February, and with nearly every major payer pledged to extend the outcome-aligned framework beyond Original Medicare's 33 million beneficiaries into Medicare Advantage, Medicaid, and commercial, cohort selection will separate companies with a durable payment thesis from those without one.
At Q1's pace, 2026 closes with roughly 50 mega deals — nearly double last year. Whether Q2's final figures (Rock Health mid-year report, mid-July) confirm the pace is the first checkpoint; whether the concentration broadens or hardens is the question that matters for everyone outside the top tier.
On exits: watch for the first S-1. Virta has said it expects IPO readiness this year; Whoop's reported ambitions and the PE-backed candidates in banker talks (Zelis, Ensemble) mean a single successful listing in H2 could reopen the queue for 2027.
Basis Points Health is an independent quarterly publication tracking private equity and venture capital investment into AI-native healthcare companies. We write for operators, investors, and strategists who need the signal without the noise.
We are not affiliated with any investment fund, healthcare system, or technology vendor. No company pays to appear in our deal register or investment thesis sections. Our editorial positions reflect our own analysis of publicly available data and industry reporting.
Each issue covers one full quarter of deal activity — funding rounds, PE transactions, M&A, and public market exits — with a consistent analytical framework that makes issues comparable over time. We believe the healthcare AI market is large enough and fast-moving enough that a rigorous, design-quality quarterly record is genuinely useful.
LPs, GPs, and family offices tracking the healthcare AI category across venture and PE. Use this as a quarterly deal log and market temperature check alongside your own sourcing.
AI healthcare startup founders tracking competitive funding, comparable valuations, and which investors are active in your category. Understanding the capital landscape is part of running the business.
Corporate development and strategy teams at health systems, payers, and pharma companies tracking which AI companies are attracting capital and why — and what that signals about where the market is going.
A curated, design-quality primary reference for the healthcare AI funding landscape — with deal data, sector breakdowns, and investment thesis analysis in one place.
Every deal in the register meets a defined set of criteria, unchanged from Issue No. 1 so that issues remain comparable. We publish these openly so readers can assess what is and isn't included — and flag anything we may have missed.
| Criterion | Our Standard | Rationale |
|---|---|---|
| Minimum Round Size | $100M+ for full deal register entry; $25M+ tracked but not individually profiled | Below $25M, deals are numerous and signal is low. We track the full market but profile only rounds large enough to indicate conviction at fund scale. This issue includes select sub-$100M rounds where they anchor a thesis (Latent, xCures, Adonis, Lassie) — flagged by their amounts. |
| AI Definition | Company must use machine learning, large language models, computer vision, or predictive analytics as a core product component — not merely as a back-end feature | We exclude companies that use AI incidentally and include only those where AI is a primary value driver. Note: with Rock Health retiring its AI-deal category, our register definition is now stricter than the headline market figures we cite. Borderline cases are noted. |
| Geographic Scope | U.S.-headquartered or U.S.-listed companies; global rounds involving a U.S. lead investor are noted separately | Reimbursement environments, regulatory frameworks, and exit markets differ significantly. U.S.-focus allows like-for-like comparison across issues. (See Alan, noted below the register.) |
| Data Sources | Rock Health quarterly and annual reports; CB Insights; Crunchbase; company press releases; SEC filings; Fierce Healthcare, Healthcare Dive, STAT News, and Health Tech Nerds coverage | We triangulate across at least two sources for every round above $100M. Figures represent announced amounts; undisclosed tranches are noted. |
| Valuation Figures | Post-money valuations reported only when publicly disclosed by company or investor | We do not estimate or model valuations. Undisclosed valuations are left blank rather than approximated. |
| Business Model Classification | B2B (sells to organizations), B2C (sells direct to consumers), B2B2C (free or subsidized to end user; monetizes via enterprise), B2G (sells to government/CMS) | Model classification matters for margin structure, sales cycle, and exit comparables. Classifications reflect primary revenue model at time of round. |
| What We Exclude | Pure biotech / therapeutics without a software AI component; medical device companies without an AI data layer; health insurance carriers; hospital systems raising capital | These segments have distinct valuation frameworks, investor bases, and exit markets. Mixing them with AI software companies distorts category-level analysis. |
See something missing or incorrect? We welcome corrections and tips — reply to any issue email, or reach us via the subscribe address.
The regulatory and reimbursement environment is the single most important external variable for AI healthcare investment returns. This tracker covers key CMS, HHS, FDA, and legislative developments as of Q2 2026.
| Item | Detail | Status |
|---|---|---|
| CMMI ACCESS ModelOutcome-aligned payment for digital health | Payment rates went live in February 2026, rewarding measurable outcomes rather than activity. Nearly every major payer has pledged to adopt the same outcome-aligned framework — extending the model's reach well beyond Original Medicare's 33 million beneficiaries into MA, Medicaid, and commercial. Inaugural cohort announcement expected in H2 2026. The most consequential payment development for digital health this cycle. | Live 2026 |
| CMS-0057-F — Electronic Prior AuthorizationInteroperability & prior auth final rule | Requires health insurers to make prior authorization fully electronic by January 2027. With the deadline under nine months out, the market is treating it as a forcing function — driving deal activity across the full stack, from Latent's Series A to broader RCM platforms with prior-auth exposure. Companion CMS rules mandate 72-hour (urgent) and 7-day (standard) payer response windows. | Deadline Jan 2027 |
| HHS / ONC Interoperability PushHealth Tech Ecosystem & info blocking | Fresh HHS leadership and a refocused ONC are pushing toward data liquidity through interoperability requirements and stepped-up information blocking enforcement. Consumer demand to access and use personal health data — amplified by the new consumer AI health platforms — adds demand-side pressure. A structural tailwind for data-layer companies. | In Progress |
| FDA Guidance — Low-Risk Wellness ProductsConsumer digital health clarity | Clearer FDA guidance on low-risk general wellness products has reduced regulatory ambiguity for direct-to-consumer digital health — one of the tailwinds Rock Health credits for the new wave of AI-native consumer platforms attracting investment in 2026. | Active |
| Telehealth FlexibilitiesExtended coverage authorities | Telehealth flexibilities have been extended through 2027, sustaining reimbursement for virtual care models and supporting the investment case for consumer and hybrid care platforms while a permanent framework is debated. | Through 2027 |
| FDA AI/ML-Based SaMD FrameworkSoftware-as-medical-device pathway | The FDA has cleared well over 950 AI/ML-enabled medical devices, with radiology and cardiology the largest categories. The predetermined change control plan framework — allowing iterative model updates without full re-clearance — continues to mature. But H1's Gleamer/Oxipit contrast underscores that clearance alone no longer moves valuations; adoption does. | In Progress |
| EU AI Act × MDR/IVDRCompounding European compliance burden | The parallel application of the EU AI Act and medical device regulations — which industry group MedTech Europe has criticized as an unnecessary layer of complexity — is adding an estimated 18–24 months to certification timelines for software above Class IIa. The European Commission committed €63.2M in April for AI health innovation, but for U.S. companies, European expansion carries materially higher regulatory cost than a year ago. | In Force |
Issue No. 1 promised expanded failures and distress coverage — here it is. H1 2026's ledger is defined less by shutdowns than by a collapsed mega-deal, a cautionary tale that now shadows an entire sub-category, and an accelerating acqui-hire market for AI talent.
Our failures tracking methodology continues to develop. If you are aware of shutdowns, acqui-hires, collapsed transactions, or significant down rounds we should be tracking, we welcome tips — reply to any issue email.
Rock Health Q1 2026 Funding Overview (April 2026); Rock Health 2025 Annual Funding Report (January 2026); CB Insights State of Digital Health Q1'26 (April 2026); PwC US Deals 2026 Midyear Outlooks — Health Services, Medtech, Pharma (June 2026).
Fierce Healthcare Fundraising Tracker '26 and digital health coverage; Healthcare Dive; MedTech Dive; Health Tech Nerds weekly briefings; Crunchbase Megadeals Board; Galen Growth HealthTech Alpha; company press releases and investor communications.
Individual deal figures sourced from company press releases and public filings where available. Headline market figures follow Rock Health's U.S. digital health definition for continuity with Issue No. 1; CB Insights figures, which use a broader definition, are cited and labeled where they add signal. Figures as of July 2, 2026.
Basis Points Health lands in your inbox four times a year — covering the biggest funding rounds, PE moves, IPO activity, and the investment theses driving capital into AI-native healthcare. No noise, no daily emails. Just the quarterly signal.
Quarterly cadence · No spam · Unsubscribe anytime · Email provider TBD
Each issue of Basis Points Health covers one quarter of AI healthcare investment activity. All past reports remain freely accessible below — no paywall, no login.
IMPORTANT DISCLAIMER: This report is prepared for informational and discussion purposes only and does not constitute investment advice, a recommendation, or an offer or solicitation to buy or sell any security. The information contained herein has been obtained from sources believed to be reliable, but its accuracy and completeness cannot be guaranteed. Past performance is not indicative of future results.
All figures are sourced from publicly available industry reports and company announcements as of July 2, 2026. Q2 2026 figures are preliminary pending Rock Health's mid-year report. Market data may have changed since publication.
© 2026 Basis Points Health. All rights reserved. Reproduction without express written permission is prohibited. Report compiled July 2, 2026.